Xinjingzhiyuan Biotechnology
A company focusing on the development of TCR-T immune cell therapy drugs for solid tumors
About Xinjingzhiyuan Biotechnology
Xinjingzhiyuan Biotechnology (Neowise Biotechnology), founded in Suzhou, China, in September 2020, is a biopharmaceutical company concentrating on the development of T-cell receptor (TCR-T) cell therapy for solid tumors. The company was established by three PhDs returning from the United States, including Founder and CEO Dr. Peng Songming. Dr. Peng, a Cornell University PhD and California Institute of Technology postdoctoral fellow, has extensive experience in cancer immunotherapy. Notably, in 2016, he was the first to isolate T-cells that could recognize cancer cells directly from a patient's blood sample and was a scientific co-founder of PACT Pharma, a neoantigen-cell therapy company. This background directly informs Neowise's mission to create affordable and effective cell therapy drugs.
The company's core business revolves around developing TCR-T cell therapy drugs. Its primary market is oncology, specifically targeting solid tumors, which account for over 90% of cancers. Neowise's business model is centered on its proprietary high-throughput antigen-TCR screening platform. This technology addresses a key bottleneck in the industry by enabling the rapid and efficient discovery of natural, high-affinity TCR sequences that can target cancer-specific neoantigens. By building what it aims to be the world's largest paired antigen-TCR library, Neowise can select optimal TCRs for individual patients. These selected TCRs are then used to edit the patient's own T-cells, which are expanded and re-infused to specifically attack the tumor. Revenue generation appears to be structured around the development and commercialization of its drug pipeline and through licensing agreements, such as the one established with BeOne Medicines to develop next-generation cell therapies.
Neowise's key achievement is the creation of its target-TCR discovery and validation platform, which has already accumulated thousands of specific antigen-TCR paired datasets. This platform significantly expands the potential therapeutic targets for solid tumor patients. The company has established a 3,500-square-meter GMP facility to support process development and drug manufacturing, and multiple product pipelines have entered the investigator-initiated trial (IIT) clinical research stage. Since its inception, the company has secured significant funding, including an angel round from Baidu Ventures, a Series A round led by TF Capital, and a Series A+ round of nearly RMB 200 million, bringing total financing to well over RMB 100 million within its first year.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2026 | $28M | $138M | GEM Capital · Yuanhe Holdings · Tonggao Capital · Suzhou Angel FoF | ↗ |
| SERIES AOther financing | Mar 2023 | $28M | $110M | Leading Venture Capital · Yuanhe Yuandian · Tonggao Capital · TF Capital | ↗ |
Growth signals
Latest recorded traffic for Xinjingzhiyuan Biotechnology is 240 monthly website visits, up 166.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xinjingzhiyuan Biotechnology in its local ecosystem
The Xinjingzhiyuan Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
- LCLeading Venture Capital
- YYYuanhe Yuandian
- TCTonggao Capital
TF Capital- MPMarathon Venture Partners
- GEGEM
- ZHZhongxin Capital Holdings
Apricot Capital
GEM Capital- YHYuanhe Holdings
- SFSuzhou Angel FoF
Delian Capital
Other known investors1 additional known investor
Caltech, California Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xinjingzhiyuan Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xinjingzhiyuan Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









